<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; branding</title>
	<atom:link href="http://www.tapanray.in/tag/branding/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why Do Drug Companies Now Need More Focus On The 5th &#8220;P&#8221; Of Marketing?</title>
		<link>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing</link>
		<comments>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/#comments</comments>
		<pubDate>Mon, 07 Mar 2022 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[4 Ps]]></category>
		<category><![CDATA[5th P]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[driving]]></category>
		<category><![CDATA[Get Z]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[marketing-mix]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[purpose-driven marketing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[service]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10665</guid>
		<description><![CDATA[Astute marketers understand that over several decades, the much-known phraseology &#8211; ‘marketing mix’, has remained the bedrock of marketing a product or a service. The ‘Father of Modern Marketing’ - Philip Kotler defined this terminology as the &#8220;the set of controllable variables that &#8230; <a href="http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create Novel Marketing Pathways As Covid Mutants Keep Emerging</title>
		<link>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-novel-marketing-pathways-as-covid-mutants-keep-emerging</link>
		<comments>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/#comments</comments>
		<pubDate>Mon, 10 Jan 2022 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[approvals]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[EUA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[molnupiravir]]></category>
		<category><![CDATA[mutants]]></category>
		<category><![CDATA[novel]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[variants]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10634</guid>
		<description><![CDATA[The World’s battle against wave after wave unsettling onslaught of Coronavirus on human lives and livelihood continues, since December 2019. The first wave was triggered by the novel Covid-19 from Wuhan in China, the second by its deadly – Delta variant, &#8230; <a href="http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Marketing: The New Normal: Challenges of Change</title>
		<link>http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-marketing-the-new-normal-challenges-of-change</link>
		<comments>http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/#comments</comments>
		<pubDate>Mon, 28 Jun 2021 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[challenges of change]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitally]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[end-point]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[F2F]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price-point]]></category>
		<category><![CDATA[Problem-solving]]></category>
		<category><![CDATA[purpose-driven]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resilience]]></category>
		<category><![CDATA[savvy]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10537</guid>
		<description><![CDATA[A lot has changed in healthcare marketing prompted by the Covid pandemic. Apace with these, lots of old problems continue to remain very much the same. The aforesaid was observed in a recent article, published by WARC, on May 21, 2021. Although, &#8230; <a href="http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-marketing-the-new-normal-challenges-of-change/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Branding At Tough Times</title>
		<link>http://www.tapanray.in/pharma-branding-at-tough-times/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-branding-at-tough-times</link>
		<comments>http://www.tapanray.in/pharma-branding-at-tough-times/#comments</comments>
		<pubDate>Mon, 18 Nov 2019 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Prompt]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[Tough]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9784</guid>
		<description><![CDATA[“About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.” This appeared in an article – “The secret of successful drug launches,” published by McKinsey &#38; Company in &#8230; <a href="http://www.tapanray.in/pharma-branding-at-tough-times/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-branding-at-tough-times/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Relevant Is A Pharma Brand Name To Patients?</title>
		<link>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-relevant-is-a-pharma-brand-name-to-patients</link>
		<comments>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/#comments</comments>
		<pubDate>Mon, 26 Feb 2018 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[counter]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTC]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8832</guid>
		<description><![CDATA[Are brand names necessary for medicines? Well – its’s a contentious issue, at least, as on date. It becomes the subject of a raging debate when the same question is slightly modified to: &#8211; Are brand names necessary for prescription &#8230; <a href="http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-relevant-is-a-pharma-brand-name-to-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Marketing Practices: Why Pharma Does What It Does?</title>
		<link>http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=marketing-practices-why-pharma-does-what-it-does</link>
		<comments>http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/#comments</comments>
		<pubDate>Mon, 11 Sep 2017 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Brent]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jimenez]]></category>
		<category><![CDATA[Joe]]></category>
		<category><![CDATA[Joseph]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharma. policy]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[proposals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saunders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8408</guid>
		<description><![CDATA[It started way back &#8211; spanning across many developed countries of the world. However, probably for the first time in the last five years, an international media group focused on this issue thriving in India, with so much detail. Reuters &#8230; <a href="http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Draft Pharma Policy 2017 And Branded Generics</title>
		<link>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=draft-pharma-policy-2017-and-branded-generics</link>
		<comments>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/#comments</comments>
		<pubDate>Sun, 27 Aug 2017 23:55:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Bioavailability]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GLP]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unbranded]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[WOW]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8385</guid>
		<description><![CDATA[In its first reading, the 18-page draft Pharma Policy, 2017 gives me a sense that the Government has followed the much-desired principle of ‘walk the talk’, especially in some key areas. One such space is what Prime Minister Modi distinctly &#8230; <a href="http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/draft-pharma-policy-2017-and-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescriptions in Generic Names Be Made A Must in India?</title>
		<link>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescriptions-in-generic-names-be-made-a-must-in-india</link>
		<comments>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/#comments</comments>
		<pubDate>Mon, 24 Apr 2017 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aaadhar]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[identification]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[INN]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PMJAY]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Surat]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8196</guid>
		<description><![CDATA[Would prescriptions in generic names be made a must in India? Yes, that’s what Prime Minister Modi distinctly hinted at on April 17, 2017, during the inauguration function of a charitable hospital in Surat. To facilitate this process, his government &#8230; <a href="http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma In 2016 Rio Olympics</title>
		<link>http://www.tapanray.in/pharma-in-2016-rio-olympics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-in-2016-rio-olympics</link>
		<comments>http://www.tapanray.in/pharma-in-2016-rio-olympics/#comments</comments>
		<pubDate>Mon, 29 Aug 2016 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[ads]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Olympics]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rio]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7785</guid>
		<description><![CDATA[On August 4, 2016, the ‘Adweek’ &#8211; a well-known weekly American advertising-trade publication, reported that even a day before the games began, the national ad sales revenue of just one major network in ‘2016 Rio Olympics’ had set a new &#8230; <a href="http://www.tapanray.in/pharma-in-2016-rio-olympics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-in-2016-rio-olympics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Power Of Color And Design In Pharma Branding</title>
		<link>http://www.tapanray.in/the-power-of-color-and-design-in-pharma-branding/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-power-of-color-and-design-in-pharma-branding</link>
		<comments>http://www.tapanray.in/the-power-of-color-and-design-in-pharma-branding/#comments</comments>
		<pubDate>Mon, 16 Nov 2015 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[blue]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[color]]></category>
		<category><![CDATA[design]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[purple]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Requip]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[viagra]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7274</guid>
		<description><![CDATA[On November 06, 2015, the District Court of Delaware of the United States (US) passed a temporary restraining order barring Dr. Reddy&#8217;s Laboratories (DRL) from selling in the US its generic version of AstraZeneca’s blockbuster anti-ulcerant drug Nexium, with immediate &#8230; <a href="http://www.tapanray.in/the-power-of-color-and-design-in-pharma-branding/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-power-of-color-and-design-in-pharma-branding/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
